Evidence map›Paper›PMID 34721404›Full record

ArticleFrontiers in immunology2021

Efficacy and Safety of Dupilumab in Moderate-to-Severe Bullous Pemphigoid.

Yihua Zhang, Qiuyun Xu, Lihong Chen, Jiawen Chen, Jing Zhang, Ying Zou, Ting Gong, Chao Ji

Open access · goldAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
58citing papers in PubMed, 6 pooled it
10.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

58 citing papers in PubMed, 6 syntheses or guidelines pooled it, 85 citations in OpenAlex.

  1. Pooled it
  2. Interventions for bullous pemphigoid.The Cochrane database of systematic reviews · 2023
    Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Bullous pemphigoid burden of disease, management and unmet therapeutic needs.Journal of the European Academy of Dermatology and Venereology : JEADV · 2025
    Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yihua ZhangDepartment of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Qiuyun XuDepartment of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Lihong ChenDepartment of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Jiawen ChenDepartment of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Jing ZhangDepartment of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Ying ZouDepartment of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Ting GongCentral Laboratory, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Chao JiDepartment of Dermatology, The First Affiliated Hospital of Fujian Medical University, Fuzhou, China.
Fujian Medical University · CNFirst Affiliated Hospital of Fujian Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Bullous pemphigoid (BP) is an autoimmune blistering disorder that predominantly affects the elderly. As the main treatment for BP, systemic corticosteroids are often limited by their side effects. Safer treatment modalities are therefore needed. Dupilumab is a biologic agent used to treat BP in recent years. Methods: Medical records of patients with moderate-to-severe BP were retrospectively reviewed. Twenty-four patients were included (follow-up period: 32 weeks), eight of whom received dupilumab in combination with methylprednisolone and azathioprine (dupilumab group) while the other 16 patients received methylprednisolone and azathioprine (conventional group). Response to dupilumab was evaluated by comparison of several parameters (time to stop new blister formation, time to reduce the systemic glucocorticoids to minimal dose, and total amount of methylprednisolone). Results: The median age of patients in the dupilumab and conventional groups were 64.50 years (range: 22-90 years) and 64.50 years (range: 17-86 years), respectively. The median duration of disease before admission in the dupilumab group was 2 months (range: 1-240 months) and 2.5 months (range: 1-60 months) in the conventional group. The median time to stop new blister formation was 8 days (range: 1-13 days) and 12 days (range: 5-21 days) in patients of the dupilumab and conventional groups, respectively ( Conclusions: Dupilumab in addition to methylprednisolone and azathioprine seems superior to methylprednisolone/azathioprine alone in controlling disease progression and accelerating the tapering of glucocorticoids.

Indexed as

AdolescentAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAzathioprineDrug TaperingDrug Therapy, CombinationFemaleHumansImmunosuppressive AgentsMaleMethylprednisoloneMiddle AgedPemphigoid, BullousRemission InductionAntibodies, Monoclonal, HumanizedAzathioprinedupilumabImmunosuppressive AgentsMethylprednisolonebullous pemphigoidcorticosteroid-sparedupilumabIL-4/IL-13pruritus

Identifiers

PMID34721404
PMCPMC8552038
OpenAlexW3207627503

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.